Wells Fargo & Company Edgewise Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 22,357 shares of EWTX stock, worth $671,380. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,357
Previous 23,241
3.8%
Holding current value
$671,380
Previous $418,000
42.58%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding EWTX
# of Institutions
194Shares Held
100MCall Options Held
2.17MPut Options Held
410K-
Orbimed Advisors LLC San Diego, CA15MShares$451 Million9.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$268 Million3.32% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$181 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.84MShares$175 Million1.67% of portfolio
-
Novo Holdings Hellerup, G75.55MShares$167 Million10.36% of portfolio
About Edgewise Therapeutics, Inc.
- Ticker EWTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,171,700
- Market Cap $1.9B
- Description
- Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...